Similar articles for PMID: 34475083

Year	Number of Results
2014	1
2015	3
2016	6
2017	7
2018	10
2019	30
2020	46
2021	65
2022	38
2023	13
2024	0

1

Lenvatinib Rechallenge After Ramucirumab Treatment Failure for Hepatocellular Carcinoma.

Komatsu S, Yano Y, Kido M, Kuramitsu K, Gon H, Fukushima K, Urade T, So S, Yanagimoto H, Toyama H, Kodama Y, Fukumoto T. Komatsu S, et al. Anticancer Res. 2021 Sep;41(9):4555-4562. doi: 10.21873/anticanres.15268. Anticancer Res. 2021. PMID: 34475083

2

Initial Experience of Ramucirumab Treatment After Lenvatinib Failure for Patients With Advanced Hepatocellular Carcinoma.

Kuzuya T, Ishigami M, Ito T, Ishizu Y, Honda T, Ishikawa T, Fujishiro M. Kuzuya T, et al. Anticancer Res. 2020 Apr;40(4):2089-2093. doi: 10.21873/anticanres.14167. Anticancer Res. 2020. PMID: 32234901 Clinical Trial.

3

Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib.

Kodama K, Kawaoka T, Namba M, Uchikawa S, Ohya K, Morio K, Nakahara T, Murakami E, Yamauchi M, Hiramatsu A, Imamura M, Chayama K, Aikata H. Kodama K, et al. Oncology. 2019;97(2):75-81. doi: 10.1159/000499715. Epub 2019 Jun 26. Oncology. 2019. PMID: 31242488

4

Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.

Ikeda K, Kudo M, Kawazoe S, Osaki Y, Ikeda M, Okusaka T, Tamai T, Suzuki T, Hisai T, Hayato S, Okita K, Kumada H. Ikeda K, et al. J Gastroenterol. 2017 Apr;52(4):512-519. doi: 10.1007/s00535-016-1263-4. Epub 2016 Oct 4. J Gastroenterol. 2017. PMID: 27704266 Free PMC article. Clinical Trial.

5

Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment.

Yamashige D, Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Okubo S, Muraishi N, Kajiwara A, Iritani S, Fujiyama S, Hosaka T, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Kumada H. Yamashige D, et al. Oncology. 2021;99(3):169-176. doi: 10.1159/000510754. Epub 2020 Nov 18. Oncology. 2021. PMID: 33207358 Free PMC article.

6

Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma.

Ikeda A, Aoki K, Kawamura M, Yamaguchi D, Kokuryu H. Ikeda A, et al. Intern Med. 2021;60(3):403-407. doi: 10.2169/internalmedicine.5552-20. Epub 2021 Feb 1. Intern Med. 2021. PMID: 33518611 Free PMC article.

7

C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib.

Hayashi T, Shibata M, Oe S, Miyagawa K, Honma Y, Harada M. Hayashi T, et al. PLoS One. 2020 Dec 22;15(12):e0244370. doi: 10.1371/journal.pone.0244370. eCollection 2020. PLoS One. 2020. PMID: 33351844 Free PMC article.

8

Reduction in Tumor Stain at 2 Weeks after Treatment Initiation Is a Predictor of the Efficacy of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma.

Kunimoto H, Shakado S, Tanaka T, Takata K, Yamauchi R, Fukuda H, Tsuchiya N, Yokoyama K, Morihara D, Takeyama Y, Hirai F, Sakisaka S. Kunimoto H, et al. Oncology. 2020;98(11):779-786. doi: 10.1159/000509005. Epub 2020 Sep 2. Oncology. 2020. PMID: 32877911

9

Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib.

Ando Y, Kawaoka T, Suehiro Y, Yamaoka K, Kosaka Y, Uchikawa S, Kodama K, Morio K, Fujino H, Nakahara T, Murakami E, Yamauchi M, Tsuge M, Hiramatsu A, Fukuhara T, Mori N, Takaki S, Tsuji K, Nonaka M, Hyogo H, Aisaka Y, Masaki K, Honda Y, Moriya T, Naeshiro N, Azakami T, Takahashi S, Imamura M, Chayama K, Aikata H. Ando Y, et al. Oncology. 2020;98(11):787-797. doi: 10.1159/000509387. Epub 2020 Sep 3. Oncology. 2020. PMID: 32882687

10

Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.

Kim S, Kim KH, Kim BK, Park JY, Ahn SH, Kim DY, Kim SU. Kim S, et al. J Gastroenterol Hepatol. 2021 May;36(5):1317-1325. doi: 10.1111/jgh.15355. Epub 2020 Dec 28. J Gastroenterol Hepatol. 2021. PMID: 33217054

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

189 results

Results by year